Most OxyContin prescriptions will now not be lined in Cigna group well being plans beginning in January, the insurance coverage big introduced.
The transfer is an try to assist stem the opioid epidemic that has unfold throughout america, firm officers stated.
“Our focus is on serving to clients get probably the most worth from their drugs — this implies acquiring efficient ache reduction whereas additionally guarding in opposition to opioid misuse,” Cigna Chief Pharmacy Officer Jon Maesner stated in a press release.
Though OxyContin will not be an choice for Cigna clients until a health care provider deems it “medically essential,” the corporate stated it has signed a contract with the maker of one other opioid, often called Xtampza ER.
Xtampza is “an [OxyContin] equal with abuse-deterrent properties,” the corporate stated. “Xtampza ER’s abuse-deterrent platform permits the product to take care of its extended-release profile even when lower, crushed or chewed.”
OxyContin additionally has abuse-deterrent properties, CNN reported, comparable to being harder to crush. One examine did discover that Xtampza was tougher to abuse than OxyContin, however that analysis was carried out by Xtampza’s producer, Collegium Pharmaceutical, in accordance with the information service.
One drug security skilled famous that abuse deterrence has limitations.
“Folks do not acknowledge that simply because they’re tougher to tamper with does not make them any much less addictive or any more practical in power non-cancer ache,” Dr. Caleb Alexander, director of the Johns Hopkins Heart for Drug Security and Effectiveness, instructed CNN.
Alexander added that monetary elements could have performed an element in Cigna’s determination to drop OxyContin.
However Dr. Charles Argoff, president of the American Academy of Ache Medication Basis, instructed CNN, “We’re taking place a really dangerous slippery slope if we permit payers to solely make selections solely on monetary